Buy or sell guide
Should I Buy NVS Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for Novartis AG.
Updated 2026-06-21
Wall Street currently rates NVS hold with a 12-month price target of $170 (+15.6% upside). The sections below cover the bull case, key risks, and latest earnings context for NVS.
Wall Street
Hold25 analystsConsensus target
$170 target (+15.6%)Current price $147.08Analyst sentiment
No recent analyst posts capturedWaiting for fresh postsEarnings context
EPS miss 5.7%Reported Tue Apr 28Wall Street verdict
Should I Buy NVS Stock? Here's What Analysts Think
25 analysts currently cover NVS. Below is their consensus rating, price target range, and implied upside.
According to 25 analysts, Novartis AG (NVS) is rated Hold with a consensus 12-month price target of $170 — representing 16% upside from today's price of $147. The bull case target is $170, the bear case is $170.
NVSHold
From 25 analyst ratings- Current price
- $147.08
- Consensus Target
- $170 (+15.6% upside)
- Forward P/E
- 16.9x
- Coverage
- 25 analyst ratings
High target$170
Low target$170
At $147.08, the consensus setup implies +15.6% versus the 12-month target.
- 6 of 25 analysts lean Buy or Strong Buy, while 17 stay on Hold and 2 lean bearish.
- NVS trades at roughly 16.9x forward earnings, so the bull case still depends on growth staying strong.
- Analysts span a wide range from $170 to $170, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for NVS right now.
Analyst ratings update weekly. Get NVS's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
Live commentary on X
What Analysts Are Saying About Novartis AG Right Now
Real posts from high-reach stock analysts mentioning NVS, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about NVS in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy NVS?
Is NVS a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for NVS before you decide whether to buy, hold, or sell.
Current setup
NVS missed estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Strong Earnings PerformanceNovartis reported an Earnings Per Share (EPS) of $2.03, surpassing consensus estimates, indicating strong profitability.
- Positive Analyst UpgradesSeveral analysts have upgraded NVS, issuing 'buy' ratings, reflecting confidence in the company's future performance.
- Limited Tariff ExposureThe CEO indicated that Novartis expects to have essentially no tariff exposure by mid-2026, which could positively impact operations.
- Beneficial Spin-offs ImpactThe transition to a pure-play innovative medicines company after spin-offs has improved valuation and margins.
- Robust Capital Allocation StrategyNovartis' strategy includes value-accretive acquisitions, a significant share buyback program, and dividend growth.
- Long-Term Growth ProjectionsForecasts predict a stock price of $243.17 by the end of 2030, indicating substantial long-term growth potential.
Wall Street rates NVS hold, giving the bull case institutional backing from 25 analysts.
Watch Out For
What can break the setup quickly
- Analyst Downgrades and HoldsSome analysts have issued 'hold' ratings, indicating uncertainty about short-term performance and limited price appreciation.
- Reduced Earnings EstimatesAnalysts have lowered FY2027 earnings per share estimates, suggesting potential challenges in meeting growth expectations.
- Stock Price VolatilityNVS has shown significant fluctuations in stock price, with a notable difference between its 52-week high and low.
- Intense Market CompetitionThe pharmaceutical sector's competitiveness poses challenges for Novartis in maintaining market share against new therapies.
- Generic Erosion RisksKey product patent expirations and faster-than-expected generic erosion could pressure operating profit in 2026.
- Disappointing Q1 2026 ResultsFirst-quarter results fell short of expectations, with net sales declining year-over-year due to increased R&D investments.
Watch whether new negative commentary on NVS points to these structural risks or is simply reacting to short-term price moves.
NVS Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $1.99 vs $2.11 est.Miss 5.7%
- Revenue
- $13.1B vs $13.4B est.Miss 2.4%
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into NVS consensus models and risk factors.
View Analysis
Should I Buy NVS?
Wall Street verdict, signals, and target summaries.
See Verdict
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
NVS — Frequently Asked Questions
Quick answers to the most common questions about buying NVS stock.
Should I buy NVS stock right now?
Verdict
NVS has modest upside — analysts rate it "Hold" with a $170 target, implying +15.6% from today's $147.08. This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy NVS?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Hold" with +15.6% upside to the $170 target.
What is the price target for NVS stock?
Price Target
NVS's consensus 12-month price target is $170, set by 25 Wall Street analysts. The bull case high is $170 and the bear case low is $170. From the current price of $147.08, this implies +15.6% upside.
Is NVS overvalued or undervalued?
Valuation
NVS appears undervalued — the $170 consensus target is +15.6% above today's $147.08. It trades at a forward P/E of 16.9x. Targets range from $170 (bear) to $170 (bull), reflecting different assumptions about growth and margins.
Should I buy NVS before earnings?
Earnings
NVS reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Hold" with a $170 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about NVS stock?
Coverage
Of 25 analysts covering Novartis AG (NVS): 0 Strong Buy, 6 Buy, 17 Hold, 2 Sell, 0 Strong Sell — a "Hold" consensus. The 12-month price target is $170 (range $170–$170). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying NVS stock?
Risks
2 of the 25 analysts covering NVS rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Novartis AG.
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.